If you'd like to support us and get something great in return, check out our PDF OSCE Checklist Booklet containing over 100 OSCE checklists in PDF format.
Table of Contents
Ovarian cancer is one of those nightmare cancers: its vague, insidious onset means that it tends not to present until it is too late, and there is currently no effective screening programme in place to detect it at an earlier stage. Like endometrial cancer, it tends to affect older women and it is vital to consider it a possibility in women over 60 with vague abdominal or urinary symptoms.
Ovarian cancer tends to present with a pelvic mass, so I’ve included a differential diagnosis for this. I’ve also described efforts to develop an ovarian screening programme – the UKFOCSS trial is currently underway to investigate its effectiveness.
Anatomy of the ovaries
the ovaries are a pair of small oval-shaped organs located in the female pelvis. They are the female equivalent of the testes. They function as gonads by producing female germ cells called ova, and also as endocrine glands which secrete the female sex hormones oestrogen and progesterone.
they lie on either side of the body of the uterus beneath the uterine tubes, within a double-layered sheet of peritoneum called the broad ligament.
they consist of an outer cortex, which contains the ovarian follicles, and an inner medulla containing blood vessels, nerves and lymphatics.
the ovaries are surrounded by a thin fibrous capsule called the tunica albuginea, which is covered externally by a modified layer of peritoneum called the germinal epithelium.
the fimbriae of the uterine tubes drape over the ovaries and act to “catch” the ova after they are released and guide them into the uterus.
they are usually located on the lateral wall of the pelvis in a depression known as the ovarian fossa, with the external iliac vessels above, the obturator nerve laterally, and the internal iliac vessels and ureter running behind them. However, their position can be extremely variable and they tend to move around a lot during and after pregnancy.
they are held in place by ligamentsconnecting them to other structures – the ovarian ligament is continuous with the round ligament and connects them to the uterus, and the suspensory ligament of the ovary (or infundibulopelvic ligament) is part of the broad ligament which connects them to uterine tubes and the lateral wall of the pelvis, and transmits the ovarian vessels and nerves.
the ovaries are the only totally intraperitoneal organs in the body – this is important as it means that ectopic pregnancies can implant onto abdominal organs, and ovarian cancer can easily metastasise across the peritoneal cavity (this is known as transcoelomic spread).
Physiology of the ovaries
at birth, the ovaries contain 1-2 million ova, but only about 300-400 will ever undergo maturation
the ovaries usually take it in turns each month to mature and release an ovum (ovulate) during the menstrual cycle – the ovum enters the uterine tube, where it can undergo fertilisation by a sperm and develop into a fetus. If it is not fertilised, it is shed along with the endometrial lining of the uterus.
this process is triggered by the pituitary hormones FSH and LH
the developing ovarian Graafian follicle produces oestrogen, which stimulates the proliferation of the endometrium and changes in cervical mucus which makes it more welcoming to sperm. It also causes a wide variety of systemic effects.
after ovulation has occurred, the corpus luteum produces progesterone which triggers changes in the endometrium to make it more receptive to implantation.
for more detail on the menstrual cycle, see here for the Geeky Medics guide
ovarian cancer is a malignant neoplasm arising from the tissues of the ovary – it is the leading cause of death from gynaecological cancer in the UK
ovarian cancer accounts for 4% of cancers in UK women (about 7000 cases per year)
it is the fifth most common cancer and causes 5.6% of cancer deaths (about 4000 per year)
there is a lifetime risk of 2.0%, or 1 in 51, for women in the UK
it has a peak incidence in women in their 60s and 70s and is rare under the age of 40
incidence has decreased over the past 10 years, possibly due to increased use of the OCP
ovarian cancer is almost twice as common in developed countries than in the developing world
Aetiology and risk factors
ovarian cancer is believed to result from damage to the ovarian surface epithelium during ovulation
the “theory of incessant ovulation” basically states that the more a woman ovulates in her lifetime, the higher her risk of ovarian cancer, due to the increased cumulative damage to the epithelium and the increased risk of mutations during its subsequent repair and regeneration
factors leading to “incessant ovulation” include early menarche, late menopause, delayed childbearing, nulliparity, use of HRT for >5 years, use of fertility drugs such as clomiphene to stimulate ovulation, and increasing age
previous ovarian disease, such as ovarian cysts (2-9x risk) or endometriosis (1.5x risk), can increase risk, probably through similar mechanisms
pelvic radiotherapy for previous gynaecological cancers or lymphoma (1-2x risk)
previous breast cancer (2-4x risk) or ovarian cancer (obviously)
smoking is a proven risk factor for some types of ovarian cancer
obesity, diabetes and sedentary lifestyle can also increase risk, especially in younger women
occupational carcinogen exposure – asbestos is a known ovarian carcinogen (3-5x risk)
family history is important as several inherited genetic traits can significantly increase risk, for example, BRCA1 (46% risk by age 70), BRCA2 (12% risk by age 70) and HNPCC (12% lifetime risk).
being tall is a risk factor, although no-one really knows why
protective factors include multiparity (>3 pregnancies), breastfeeding, OCP use, hysterectomy, tubal ligation, exercise and aspirin
Epithelial ovarian tumours (~90%)
derived from surface coelomic epithelium, generally affect the over 50s
7% metastases from other sites – gastric (Krukenberg tumour), colorectal, breast, endometrial, cervical, lymphoma, leukaemia
Symptoms of ovarian cancer can include:
its insidious onset means that up to 75% of patients present with symptoms of advanced disease due to the mass effects of the tumour
non-specific GI symptoms such as bloating or indigestion (often misdiagnosed as IBS)
gradually increasing abdominal distension (often misdiagnosed as “middle-aged spread”)
increasing tumour size results in pressure effects causing chronic abdominal, pelvic or back pain, urinary frequency/urgency (pressure on the bladder), constipation/altered bowel habit/bowel obstruction (pressure on bowel), leg swelling and DVT/PE (pressure on pelvic veins)
abnormal vaginal bleeding can also be a symptom
symptoms of metastatic disease include pleural effusion, ascites, weight loss and fatigue
less commonly, sudden torsion, rupture or infection of the tumour in early disease can present with acute abdominal or pelvic pain – this is a blessing in disguise as it can lead to early diagnosis.
Clinical signs associated with ovarian cancer include:
general examination – cachexia, lymphadenopathy, signs of pleural effusion
GI pathology – the 6 Fs: fat, fluid, flatus, faeces, fetus, filthy big tumour
other abdominal pathology – primary peritoneal cancer, retroperitoneal sarcoma.
Diagnostic tests for women with suspected cancer include:
history and clinical examination including Cusco speculum examination and bimanual palpation
always do a pregnancy test in women of reproductive age
tumour markers are very useful in the diagnosis of ovarian cancer: CA-125 (a coelomic epithelial antigen) is elevated in 90% of cases of advanced disease and 50% of cases of early disease. It is very sensitive for ovarian cancer but not particularly specific – it can also be raised in other gynaecological cancers, GI cancers, benign abdominal and pelvic disorders, breast cancer and diseases affecting the pleura, pericardium or peritoneum. However, performed in the correct clinical context it can be very informative and should be a standard test for suspected ovarian cancer.
other tumour markers for specific types of ovarian cancer include CA19-9 (mucinous epithelial), beta-hCG and placental ALP (dysgerminomas, embryonal cancers, choriocarcinoma), AFP (endodermal sinus/yolk sac tumours), inhibin (granulosa-thecal cell tumours) and LDH (some dysgerminomas) – these are usually arranged and interpreted by a specialist gynae-oncologist.
transabdominal +/- transvaginal ultrasound should be performed to assess the mass and check for any metastases
Initial investigations are usually carried out by GPs in primary care, and the risk of malignancy index (RMI) score provides guidance on which patients to refer to gynaecology. It provides a composite assessment of risk and allows gatekeeping of referrals to specialist centres. It is calculated as menopausal status scorexultrasound assessment score x CA-125 result. A score of >200 indicates a 75% risk of cancer and should prompt referral to a specialist gynae-oncology centre. A score of <200 represents a 3% risk of cancer and should be monitored using 4-monthly CA-125 and ultrasound.
Staging investigations for patients with a high RMI score include:
imaging – CXR to check for pleural effusion or lung metastases, CT +/- MRI abdomen and pelvis to assess mass, pelvic nodes and any metastases; a PET scan may be required in advanced disease
invasive tests – pleural or ascitic tap may be required if effusion/ascites present
laparoscopy and biopsy is indicated for large cystic lesions or adnexal masses to inform further management
formal surgical staging is usually carried out as part of definitive management described below
Grading – how aggressive is it?
There are multiple grading systems available depending on the type of ovarian cancer the patient has, e.g. FIGO, WHO, Silverberg… basically they are far too complicated to cover in detail here. Generally, tumours are graded low- to high-grade, with high-grade carrying a much poorer prognosis.
Staging – how far has it spread?
Ovarian cancers are staged using the International Federation for Gynaecology and Obstetrics (FIGO) system. The TNM system can also be used, but generally, gynae-oncologists prefer to use FIGO.
The mortality figures shown are for epithelial ovarian cancers, and the prognosis varies significantly depending on the type of cancer. For example, dysgerminomas have an excellent cure rate, whereas endodermal sinus (yolk sac) tumours have a very poor prognosis.
Surgical management is generally the mainstay of treatment:
exploratory laparotomy for tumour debulking and formal surgical staging
this is a major procedure which generally comprises total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO), infracolic omentectomy, pelvic and para-aortic lymph node sampling, peritoneal biopsies, multiple pelvic washings, sampling of ascites, inspection and sampling of the underside of the diaphragm, and removal of pretty much anything else that looks suspicious e.g. bowel, appendix, liver, spleen…
maximal cytoreduction (largest residual tumour deposit <2cm) can be achieved in up to 80% of patients and significantly improves survival
a second “interval” debulking can be carried out after chemotherapy in some cases
This excellent little video from TeamCirisano on YouTube shows the removal of a large cystic ovarian mass at laparotomy. Most of the cyst fluid is drained first to prevent unnecessary spillage and seeding of cancer cells into the abdominal cavity, then the ovary and tumour are removed.
Medical therapies are generally used as adjuncts to surgery:
adjuvant chemotherapy is given to all patients >stage Ic, plus anyone stage Ia/Ib with a high-grade malignancy. The standard first-line treatment is carboplatin + paclitaxel (response rate 70-80%). Second-line agents to consider include pegylated liposomal doxorubicin (PLDH) and topotecan. Response to treatment can be monitored using CA-125 levels, which decrease if treatment is effective and increase if there is a relapse.
intraperitoneal chemotherapy has been shown to improve survival in recent trials
radiotherapy is not really used in the management of ovarian cancer as the tumours tend to be very radioresistant. It is sometimes used in early-stage low-bulk disease.
biological immunotherapy is emerging as a potential new treatment – specific monoclonal antibodies like bavacizumab (anti-VEGF) and olaparib (anti-PARP) are currently undergoing trials
advanced metastatic cancer (which is unfortunately very common) requires individualised palliative treatment with tumour debulking, chemoradiotherapy and symptom control
Follow-up and prognosis
the overall prognosis is fairly poor (42.9% 5-year survival), but varies significantly depending on the stage and type of cancer (see above)
women who undergo surgery for ovarian cancer are usually followed up and monitored by a specialist gynae-oncology centre, with regular pelvic examinations and CA-125 levels
Prevention strategies: potential for screening
There are several potential future options for screening for ovarian cancer:
genetic screening can be offered to high-risk women with a significant family history of cancer (e.g. ovarian, endometrial, breast, gastric, colorectal) – this generally involves testing for BRCA1, BRCA2 and/or HNPCC. Patients who test positive for a mutation can be monitored using CA-125 levels and TVUSS, or may choose to undergo prophylactic interventions such as BSO +/- hysterectomy.
pelvic examination is not a very useful screening tool – it would take 10,000 pelvic exams to detect 1 case of early ovarian cancer!
CA-125 (cancer antigen 125) is a glycoprotein shed by epithelial tumours. The normal range is <35IU/L. It is a sensitive test for ovarian cancer but not very specific, as it can also be raised in several other cancers and a range of benign abdominal and pelvic conditions. Despite the high false-positive rate, it has been estimated that CA-125 screening could detect ovarian cancer up to 3 years earlier.
transvaginal ultrasound (TVUSS) is very useful in detecting ovarian cysts and assessing their malignant potential, but requires specialist sonographers and would be expensive to perform on a population screening basis.
It is clear that a screening programme for ovarian cancer would be greatly valued, as the disease characteristically does not present until it is at an advanced stage. CA-125 and TVUSS are both sensitive tests, but carry a 2-3% false-positive rate in postmenopausal women – this is generally considered too high, as it could potentially lead to unnecessary surgical interventions and cause harm. However, the use of the two tests together would significantly improve the reliability of screening. The UKFOCSS trial is currently underway to assess the combined effectiveness of CA-125 and TVUSS in screening for ovarian cancer in high-risk patients with a significant family history.
BruceBlaus. Licence: [CC BY 3.0]. Available from Wikimedia Commons.
James Heilman, MD. Licence: [CC BY-SA 3.0]. Available from Wikimedia Commons.
Further reading sources include:
Cancer Research UK – Cancer incidence for common cancers. Available from: [LINK].
Cancer Research UK – Ovarian Cancer. Available from: [LINK].
Medscape eMedicine. Ovarian Cancer. Available from: [LINK].
Patient UK – Ovarian Cancer. Available from: [LINK].
“SEER Survival Monograph: Cancer Survival Among Adults 1988-2001, Patient and Tumor Characteristics”. Chapter 16. Available from: [LINK].
Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. International Journal of Gynecological Pathology 2008 27:161-174.